OMNi-BiOTiC®: Platz 2 der erfolgreichsten Probiotika-Marken weltweit
OMNi-BiOTiC® has been ranked as the world's second most successful probiotic brand according to IQVIA. The milestone reflects more than 30 years of microbiome research, scientific collaboration and international expansion by the Austrian Institute AllergoSan.
OMNi-BiOTiC® has been ranked by IQVIA as the world's number two probiotic brand. What began more than 30 years ago in Graz as a pioneering project has grown into one of the leading probiotic brands worldwide.
Since the launch of its first multi-species probiotic in 1995, OMNi-BiOTiC® has focused on improving health through targeted modulation of the gut microbiome. Today, the brand is available in more than 70 countries and is supported by extensive scientific research and collaborations with universities, hospitals and research institutions worldwide.
More than 150 scientific studies have investigated the effectiveness of selected bacterial strains across a range of health indications, including immune function, metabolic health, fertility and mental health.
“The number two position worldwide is the result of more than 30 years of research, perseverance and our conviction that the microbiome plays a crucial role in human health. Scientific evidence has always been our driving force. No OMNi-BiOTiC® product reaches the market without supporting studies. The trust of millions of people around the world confirms the value of our continued investment in microbiome research together with leading scientists,” says Prof. Anita Frauwallner, Founder and CEO of Institut AllergoSan.
Christian Gsöll, Director Global Commercial Business at Institut AllergoSan, attributes the international success to scientific quality, long-term partnerships and the ability to address the specific needs of different markets. He says the company intends to further expand its international presence and make scientifically validated microbiome products available to even more people worldwide.
*According to the IQVIA Consumer Health Customized Insight Study (MAT December 2025), OTC3/ATC3: 03F1 + A7F, Sell-Out/Sell-In EUR/MNF.
Kontakt
Institut AllergoSan Pharma GmbH
Gundi Bittermann
E-Mail: presse@allergosan.at